Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ascendis Pharma A/S T.ASND


Primary Symbol: ASND

Healthcare Biotechnology
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).


NDAQ:ASND - Post by User

Ascendis Pharma A/S
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
  • 101724X
Comment by 101724on Jul 14, 2024 10:19am
186 Views
Post# 36132063

RE:ASND: Construction decision is the second half of 2024

RE:ASND: Construction decision is the second half of 2024Past presentations had a timeline of construction beginning 5 months ago with 1st production in 2H 2025. Go back and check. Then they they said a constuction decision would be made in June in time for the ASM. They never meet their timeline. I don't doubt what you posted. When they come out with a new "constuction decision" for 1H 2025, you'll be the clown. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities